Sangamo Therapeutics (NASDAQ:SGMO) has been assigned a $25.00 target price by Piper Jaffray Companies in a research report issued on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 40.06% from the stock’s current price.

A number of other research firms also recently issued reports on SGMO. Wedbush reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Jefferies Group reiterated a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Barclays started coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 target price for the company. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Wednesday, November 15th. Finally, BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Sangamo Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.83.

Shares of Sangamo Therapeutics (SGMO) traded up $0.45 on Wednesday, reaching $17.85. The company had a trading volume of 1,067,265 shares, compared to its average volume of 1,528,022. The company has a market cap of $1,510.00, a P/E ratio of -25.87 and a beta of 3.15. Sangamo Therapeutics has a 52 week low of $3.25 and a 52 week high of $18.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. During the same quarter last year, the company earned ($0.27) EPS. The firm’s quarterly revenue was up 333.0% on a year-over-year basis. equities research analysts predict that Sangamo Therapeutics will post -0.73 EPS for the current year.

In other news, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $18.00, for a total value of $212,454.00. Following the completion of the transaction, the vice president now directly owns 27,636 shares of the company’s stock, valued at approximately $497,448. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $73,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,433 shares of company stock valued at $635,246. 5.50% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Sangamo Therapeutics by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares in the last quarter. State Street Corp increased its position in Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after buying an additional 636,296 shares in the last quarter. RA Capital Management LLC acquired a new position in Sangamo Therapeutics during the 2nd quarter valued at about $11,000,000. Northern Trust Corp increased its position in Sangamo Therapeutics by 4.9% during the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after buying an additional 44,656 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in Sangamo Therapeutics by 93.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after buying an additional 335,595 shares in the last quarter. 64.33% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/04/sangamo-therapeutics-sgmo-given-a-25-00-price-target-at-piper-jaffray-companies.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.